EMCURE Emcure Pharmaceuticals Q4 FY25 results (Jan–Mar 2025) and concall
Emcure Pharmaceuticals delivered strong Q4 and full-year FY25 results, driven by robust domestic and international growth. The company successfully integrated Sanofi's cardio business, expanded its presence in Canada with Mantra, and launched strategic products in derma and women's health. Management provided optimistic guidance for FY26, emphasizing execution, margin expansion, and a target to become debt-free by year-end.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2,002 | 1,963 | 2,116 |
| EBITDA | 381 | 355 | 402 |
| Net profit | 202 | 156 | 197 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
